PMID- 38288188
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20240131
IS  - 2168-8184 (Print)
IS  - 2168-8184 (Electronic)
IS  - 2168-8184 (Linking)
VI  - 15
IP  - 12
DP  - 2023 Dec
TI  - Intravenous Immunoglobulin Induced Transaminitis.
PG  - e51347
LID - 10.7759/cureus.51347 [doi]
LID - e51347
AB  - Intravenous immunoglobulin (IVIG) is a common therapeutic modality used in 
      immune-mediated neuropathy. While the therapeutic benefits are well known, 
      adverse reactions have been reported. One such adverse event, though rare, is 
      transaminitis, which appears to be a transient and a self-limiting adverse 
      reaction. Though most of the cases implicate the stabilizing agent to be the 
      culprit, the exact mechanism is unknown. Thus far, it has been speculated that 
      maltose, which has been commonly used as a stabilizer, is the cause of IVIG 
      transaminitis. We present a unique case of a patient who developed transaminitis 
      post-IVIG in which glycine was used as a stabilizing agent. We aim to draw a 
      potential association between IVIG therapy and the development of transaminitis, 
      thereby providing insight into the underlying mechanisms, as well as clinical 
      features, and possibly encouraging further research on this topic.
CI  - Copyright (c) 2023, Vijaya Prakash et al.
FAU - Vijaya Prakash, Aviraag
AU  - Vijaya Prakash A
AD  - Internal Medicine, Saint Vincent Hospital, Worcester, USA.
FAU - Parvathaneni, Aparna
AU  - Parvathaneni A
AD  - Internal Medicine, Gandhi Medical College, Hyderabad, IND.
FAU - Malempati, Sarat
AU  - Malempati S
AD  - Internal Medicine, Saint Vincent Hospital, Worcester, USA.
FAU - Keilson, Gary
AU  - Keilson G
AD  - Neurology, Saint Vincent Hospital, Worcester, USA.
LA  - eng
PT  - Case Reports
DEP - 20231230
PL  - United States
TA  - Cureus
JT  - Cureus
JID - 101596737
PMC - PMC10824542
OTO - NOTNLM
OT  - elevated liver enzyme
OT  - intravenous immunoglobulin (ivig)
OT  - ivig treatment
OT  - liver damage
OT  - small fiber neuropathy
COIS- The authors have declared that no competing interests exist.
EDAT- 2024/01/30 06:42
MHDA- 2024/01/30 06:43
PMCR- 2023/12/30
CRDT- 2024/01/30 03:39
PHST- 2023/12/30 00:00 [accepted]
PHST- 2024/01/30 06:43 [medline]
PHST- 2024/01/30 06:42 [pubmed]
PHST- 2024/01/30 03:39 [entrez]
PHST- 2023/12/30 00:00 [pmc-release]
AID - 10.7759/cureus.51347 [doi]
PST - epublish
SO  - Cureus. 2023 Dec 30;15(12):e51347. doi: 10.7759/cureus.51347. eCollection 2023 
      Dec.